Background: To optimise positive outcomes, the design of new pharmacy services should
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Background
The role of the pharmacist and community pharmacy has evolved from being principally centred on medicines supply to include a broader focus on medicines management, adherence support and promoting the judicious, appropriate, safe and efficacious use of medicines in the community. 1, 2 Pharmacists are amongst the most frequently visited, available and trusted health professionals in the community setting. [3] [4] [5] [6] The accessibility of pharmacy for most consumers reinforces its potential to promote general community health, but also self-management and optimal use of medicines by those with chronic conditions.
Pharmacy services other than dispensing have been reported to be beneficial in some settings to assist the management of selected chronic condition(s), leading to improved clinical outcomes, quality of life (QoL) and reduced healthcare utilisation. [7] [8] [9] [10] Services that a pharmacist could potentially offer to help consumers and their carers effectively manage chronic conditions include medication reviews, education and information, safety monitoring through reporting adverse drug reactions or interactions or both, supporting compliance through dose administration aids, and liaising with a person's General Practitioner (GP) and other health providers as part of a care plan. 11 Perhaps more contentiously, in selected countries, pharmacists can also prescribe in a range of models across varying scopes of practice. 12, 13 Despite the potential benefits of pharmacy-led services, there is little evidence available from the consumer perspective about the acceptability or preferred design of new or innovative pharmacy services. 14 The few studies that have examined consumer preferences have reported some support for extended pharmacy roles, such as prescribing in England and Scotland, where pharmacist prescribing is now comparatively well established. 15, 16 One
Australian study reported support for the delivery of specialised asthma services through community pharmacy. 17 In other areas, it is now recognised that to provide optimal benefit for consumers and carers and be responsive to their needs, the design of new services should consider the preferences of consumers. Indeed, the benefits of considering consumer preferences in M A N U S C R I P T
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5 healthcare reform and service design have been widely recognised. [18] [19] [20] Consumers bring a unique perspective, which can promote the relevance, responsiveness, quality and safety of health service delivery. Furthermore, if consumers are engaged in the development of services, it is more likely that they will access these services, form partnerships around their care, and adhere to recommended management plans, ultimately leading to improved health outcomes. 21 This is particularly important for populations with unique needs, such as young people who experience barriers to healthcare access and unmet health needs that youthfriendly pharmacy services could address. 22, 23 There is a clear need for a greater understanding of preferred pharmacy services from the consumer perspective, to harness the opportunity for pharmacy to develop innovative health and medicines services to benefit the community.
This study is part of a wider project focused on consumers' perceptions of chronic conditions, treatment burden, and the engagement of community pharmacy in chronic condition management. The primary aim of this sub-study was to examine the relative importance of different pharmacy service characteristics for consumers with chronic condition(s) and carers of people with these condition(s), and the trade-offs that are made when choosing between pharmacy services. A secondary aim was to investigate the similarities and differences between consumer and carer preferences, and the perceptions of health professionals about consumer preferences. Given that health professional perceptions are likely to affect the design and delivery of services, agreement between these parties is critical. Several studies have investigated pharmacist preferences for an extended role, 24, 25 but none have directly compared the preferences of consumers and perceptions of health professionals for the preferred characteristics of pharmacy services.
Methods
A discrete choice experiment (DCE) was employed to elicit preferences for pharmacy services. The DCE is a choice-based preference elicitation method, with a theoretical foundation in Random Utility Theory and Lancaster's Theory of Value. [26] [27] [28] It is an established method for assessing preferences for healthcare and the trade-offs participants are willing to make between different desirable characteristics of a healthcare service, including in contexts related to the management of chronic conditions. 29, 30 The method has been M A N U S C R I P T
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6 applied previously to elicit preferences related to pharmacy and medicines use, 14 including measuring consumer preferences for self-care or professional advice for minor illness, 31 and examining the strength of preference of community pharmacists for existing and potential new roles. 17, 25 DCEs typically involve a questionnaire containing a series of choices between two or more alternative products or services. . Each alternative product or service is composed of different characteristics or "attributes", and in turn each attribute can take on several layers (referred to as "levels"). The levels of the attributes for each alternative are varied systematically across choices and for each choice set, participants select the alternative they prefer. The relative importance of improvements in the attributes and the trade-offs individuals make when choosing one alternative over another are estimated through analysis of the choice data.
(i) Identification and selection of attributes and levels
In the DCE, each participant was asked to consider four hypothetical choice sets and each choice set was composed of two different new pharmacy services. The attributes and levels used to describe each new service were developed based on extensive qualitative research involving 97 interviews with consumers and carers, [32] [33] [34] followed by 26 focus groups with consumers, carers and health professionals, during which the nominal group technique was used to rank priorities for pharmacy service delivery. 35, 36 Findings of these formative studies suggested six overarching themes were highly and consistently prioritised by participants, and were potentially meaningful to a community pharmacy service model. These themes were developed into six related pharmacy service characteristics or "attributes", each described by between two and four levels. The attributes used to describe the hypothetical new services represented the extent to which a pharmacist could provide continued medicines supply (e.g. through repeat prescribing); whether pharmacy staff could direct individuals for advice from other service or other services were provided at the pharmacy; where the pharmacy was located; how medicines could be collected; how a pharmacist could be accessed for review of advice; and an indicative average out of pocket cost for the service per month (in addition to the cost of medicines). The themes and final selected attributes and levels are provided in Table 1 . The attributes and levels in Table 1 in combination describe a full factorial design of 216 (i.e. 4*(3^3)*2) different pharmacy services, in 23,220 different pairs. 37 Experimental design theory was used to select a manageable number of pairs to present to participants, whilst maximising the efficiency (i.e. precision) of the preference estimates elicited from the choices. 29, 37 The level for each attribute was varied across alternative services according to a main effects fractional factorial experimental design, estimated using NGENE software using the Street and Burgess design approach. 38, 39 This ensured optimal statistical power for the design, whilst maintaining orthogonality in the variation of attribute levels, such that the main effects for the attribute levels could be independently estimated in the model.
The design identified 72 choice sets, with each set presenting a choice between two alternative pharmacy services. To ensure the number of choices faced by each participant was manageable, these were divided into 18 blocks of four choice sets, with participants randomised to one of the 18 blocks. An indicative choice set for consumers and carers is shown in Figure 1 . To increase realism, consumer and carer participants were given a second level "opt out" option for each choice set; they were asked to indicate whether they would take their preferred new service (i.e. service A or B), or would in reality continue to use their current pharmacy service. This question was not relevant for health professionals, who were only asked to respond according to the new pharmacy service they thought consumers would prefer. Consumer and carer participants who opted out of a new service on one or more occasions were invited to explain their reasons for doing so.
In addition to the choice sets, participants were asked questions related to their (i) socio-demographic characteristics, (ii) use of primary healthcare services and medicines, (iii) health status (including generic health-related QoL assessed using the EQ-5D-3L), 40 (iv) treatment burden (consumers and carers only), using an instrument developed by Tran and M A N U S C R I P T A C C E P T E D 42 a completed sample of 600 has a margin of error of 4%. 43 There is no consensus on appropriate sample sizes for DCE tasks to give precise estimates, and sample sizes are based on rules of thumb. 44, 45 One commonly applied rule of thumb suggests that for the proposed DCE design, a minimum sample size of 250 is required. 44 The targeted consumer and carer sample size of 600 substantially exceeds that used for the majority of DCEs in healthcare, 29 and would be expected to support the greater number of analyses to explore associations between preference and participant characteristics of interest. Health professionals were invited to participate if they resided or worked in one of the four areas, and perceived themselves to have a role that focussed on providing health services to people with chronic condition(s) in the community.
A total of 849 consumers and carers and 412 health professionals expressed an interest and were invited to participate in the DCE survey. The DCE was predominantly administered as a computer-assisted telephone interview (CATI) by a third party research company on behalf of the research team. A CATI survey approach was chosen in an attempt to maximise both the rate and completeness of response, as compared to alternative approaches, such as mail or internet based administration. 47 Surveys and study materials were mailed to participants, who were then contacted one to two weeks later and invited to participate in a telephone interview. To maximise the diversity of the sample and ensure everyone who wanted to participate was able to do so, a minority of interviews were also conducted face-to-face by the research team. Face-to-face delivery was used particularly for groups that might be considered difficult to reach via the telephone or who preferred face-toface interview, including culturally and linguistically diverse consumer and carer participants, The DCE instrument was piloted extensively, initially face-to-face in a convenience sample of adults (including consumer, carer and health professional participants). The instrument was refined, and then further piloted in 36 adults with chronic condition(s) via CATI, before the main data collection was undertaken between October 2013 and January 2014.
(iv) Data analysis
Data were analysed using regression analysis, in which the discrete choice formed the dependent variable, and the attribute levels presented for each alternative were specified as independent variables to explain choice. The analysis for consumer and carer data was based on the choice between a new service or their current service (A, B or current). In addition, qualitative reasons given for opting out of a new service were analysed thematically. The analysis of health professional data was based on the choice question allowing participants to indicate which new service (A or B) they considered their consumers would prefer.
The choice data were analysed in NLogit statistical software using mixed logit models (MXL). 48 The MXL model is a generalised analytic approach that allows for potential correlation in the multiple choice responses provided by any one individual as well as across alternatives in the choice set, and also models preference heterogeneity by allowing preferences estimated by the model to vary across the individuals in the sample. 29, 49 For each attribute level, the model estimated a mean (i.e. average) preference weight for the sample, indicating its relative importance. Participant characteristics were entered into the model to explain the variation in preference around the sample mean (i.e. preference heterogeneity).
Model specification
The utility functions for the new pharmacy services (A and B) were specified as a linear additive function of the main effects for each attribute level. For the consumer and carer model, the utility function for the current service was specified to include an alternative specific constant. All attribute levels were initially specified using effects coding.
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Preliminary analyses suggested that the levels of the cost attribute exhibited linear effects; therefore, the cost attribute was coded continuously. The MXL model was initially specified with all attribute level effects assumed to be random and following a normal distribution. 49 Attribute levels for which the standard deviation was not significant (p≤0.2, chosen as a cautious level given this provided the foundation for the next analytic step), suggesting no substantial preference heterogeneity for that attribute level, were then specified to be fixed and the model was re-estimated. All preliminary models were estimated using 25 Halton draws; the final model was then estimated using 1000 Halton draws. 49 
Modelling preference heterogeneity
Participant characteristics (Tables 2 and 3) were entered into the MXL model, to investigate the extent to which they explained any preference heterogeneity. All participant characteristics were specified as effects coded variables. There was a small proportion (≤3%) of missing data for some characteristics; missing data were coded as zero. This approach assumes the sample mean parameter estimate for a participant with missing data, allowing the retention of all choice observations in the model. A backward step regression approach was used, whereby all characteristics were entered in the model, and characteristics were then systematically removed with the least significant in explaining heterogeneity for any attribute level being removed first. The stepped process retained only those participant characteristics that were significant in explaining heterogeneity for one or more attribute levels at the significance level of p≤0.2, p≤0.1, p≤0.05 in turn. Only those characteristics that significantly explained preference heterogeneity at the 5% level were retained in the final regression model (p≤0.05).
Comparison between consumer and carer priorities and health professional perceptions of consumer priorities
The size of the coefficients in the preference models indicate the relative importance of different pharmacy services. The model coefficients were weighted such that the most preferred service improvement for each model was given 100 points, and the other improvements were given a lesser number of points in proportion to their relative importance for that sample. For each model, this was achieved for effects coded attributes by:
selecting the attribute for which there was the greatest statistically significant marginal utility associated with an improvement between any two levels (k); (ii) estimating the marginal utility for a gain from the least preferred level (R) to the most preferred level (L) (i.e. the difference in coefficients for these levels); (iii) assigning 100 points to this marginal utility gain; (iv) estimating points (Points K L ) for a gain between levels for each of the other attributes (K≠k) as a relative proportion of 100 points according to Equation 1:
For the cost attribute, points were assigned for the marginal effect associated with a $1 cost reduction per month by using the coefficient for cost as the numerator in Equation 1.
Results (1) Participant characteristics
The DCE survey was completed by 602 consumer and carer participants (70.9%
response rate) and 297 health professional participants (72.1% response rate). Data about the source of recruitment was available for 89% (536/602) consumers and carers who completed the survey. The most successful recruitment strategies were direct promotional activities by research team members in shopping centres and markets (33%), followed by flyer distribution by health providers and at health clinics and centres (21%). Data about recruitment sources was available for all 297 health professional participants, with the majority (61%) recruited via direct promotional activities conducted by the research team at lunch-time meetings, visits to health services and clinics and pharmacies located in shopping centres and email invitations sent to professional networks. The majority of surveys (548, 91.0% consumers and carers and 180, 60.6% health professionals) were conducted by CATI, with the remainder conducted face-to-face. Tables 2 and 3 summarise the characteristics of consumer and carer, and health professional participants respectively. Tables 2 and 3 On average, participants who opted out of at least one scenario provided 1.9 reasons (range 1 to 6 reasons) for choosing their current pharmacy service. In total, 907 reasons were supplied by participants who opted out of at least one scenario; the most common reasons for opting out are given in Table 4 . In summary, when clustered into broader themes, three main drivers of the choice to retain a current pharmacy service emerged; namely, person-centred services, such as a long-term personal and respectful relationship with pharmacy staff (n=349; 38.5% of all reasons); easy access to pharmacy services (i.e., speed, convenience, location and low cost; n=259; 28.6%); and continuous reliable supply of medication and availability of timely, quality advice about medicines and symptoms (n=242; 26.7%).
Participants often commented that they would not consider new pharmacy services if it meant a change to one or more of these qualities. Only a small number of participants held strong traditional views about the respective roles of GPs and pharmacists. Six of the consumer and carer characteristics included in the DCE choice sets significantly explained preference heterogeneity (p≤0.05) in the preliminary MXL models, and were therefore included in the final MXL model ( Table 5 ). The final model had a pseudo R 2 of 0.423, representing a good fit for a discrete choice model.
M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT
49 Table 5 about here
Consistent with the raw choice data, on average there was a strong propensity for consumers and carers to select their current service, rather than a new service. This is indicated by the large and highly significant constant associated with the current service (β=2.048; p≤0.001). Four of the six attributes significantly influenced choice of pharmacy service. Participants preferred to have access to a pharmacist for ongoing supply of regular medicines and for medicines they have used before for symptom flare ups, rather than having access to a doctor alone (p≤0.001). Having access to ongoing supply from a pharmacist for regular medicines tended to be preferred over access to supply from a doctor alone, but this did not reach statistical significance (p=0.725). In terms of location, on average, a one-stop health centre was preferred over a pharmacy near a participant's home or workplace, but a pharmacy near home/work was preferred to a pharmacy near their GP practices (p=0.005).
On average, participants preferred the availability of home delivery as an option over having face-to-face pick up of medicines alone (p≤0.001). They also preferred having face-to-face pick up over other types of collection that do not involve going into the pharmacy e.g. by "drive thru" in addition to face-to-face (p=0.025). Finally, participants preferred a pharmacy service that was available at a lower cost (p=0.002).
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Two attributes did not have a significant impact on choices, namely access to other health professionals and access to the pharmacist. First, choices were not influenced by the prospect of having access to other health professionals employed in the pharmacy or pharmacy staff directing individuals to other services (p=0.111). Second, choices were not influenced by the availability of the pharmacist for medicines review or advice (i.e. access to a pharmacist in the pharmacy but without having to ask, additional accessibility by phone/email/internet, or by appointment at home, or a pharmacist who remained in the dispensary but responded when asked; p=0.183 to 0.416).
Substantial variation was observed in the strength of preference across the sample for the choice of current service over a new service, and for the impact of the attributes related to continued medicines supply and cost. This variation is indicated by significant standard deviations (p≤0.01) that are large relative to the size of the mean for the related parameter (Table 5 ). There were a number of participant characteristics that significantly explained the variation in preference for each of these attributes (p≤0.05). Older participants, those who usually visit the same pharmacy, those with a lower level of education, those with a recent diagnosis of a chronic condition, and those from the Greater Perth region were more likely to choose their current service than their counterparts, all else equal. Younger participants and those in employment were less likely to choose their current service than their counterparts.
Participants taking medicines more frequently during the day were significantly more likely to value access to a pharmacist for continued supply of their regular medicines rather than relying on a doctor alone (p=0.008). Conversely, those recently diagnosed with a chronic condition were less likely to value access to a pharmacist for continued supply of regular medicines (p=0.040). Participants who were employed were significantly more averse to cost, while those from Mt Isa and North West Queensland region were less averse to cost (p≤0.01). Overall, the perceptions of health professionals were substantially consistent with the preferences of consumers and carers. On average, a one-stop health centre was expected to be preferred over a pharmacy near a consumer or carer's home/work, and a pharmacy near home/work was expected to be preferred to a pharmacy near to their GP practice (p≤0.001).
Participants expected consumers to prefer the availability of home delivery as an option over having face-to-face pick up of medicines alone (p≤0.001). There was a trend for participants to expect consumers to value the option to collect medicines without going into the pharmacy, e.g. through "drive thru" more than face-to face collection alone; however, this did not reach statistical significance at the 5% level (p=0.085). Such a trend was inconsistent with the preferences of consumers and carers, who preferred having face-to-face pick up alone over the availability of collection without going into the pharmacy, e.g. by "drive thru"
in addition to face-to-face. Four attributes did not have a significant impact on perceptions of consumer choice (p>0.05): continued medicines supply, managing ongoing conditions, medicines review or advice, and average cost per month.
Substantial variation was observed across the health professional sample in the extent to which the attributes related to continued medicines supply, managing an ongoing condition, pharmacy location and cost impacted choice (Table 6 ). There were a number of participant characteristics that significantly explained the variation in perceptions between participants for each of these characteristics (p≤0.05). First, participants who had been in their profession for less than five years were more likely to indicate their consumers would value access to a pharmacist for ongoing supply of regular medicines and for medicines they have used before for symptom flare ups, rather than having access to a doctor alone supply by a pharmacist rather than having to see a doctor for regular and symptom flare up medicines (score 100), which was valued more than one and a half times as much as pharmacy location in a one stop health centre instead of their GP practice (score 61) and twice as much as having the availability of home delivery in addition to face-to-face pick up (score 52). Other characteristics were valued to a lesser extent.
On average, health professionals expected their consumers to place highest priority on having a pharmacy located near their home/work (score 100) or in a one stop health centre (score 88) rather than at a GP practice. Pharmacy location near home/work was expected to be valued one and a half times as much as continued medicines supply for regular and symptom flare up medicines (score 67) and more than twice as much as having the availability of home delivery in addition to face-to-face pick up (score 42). Other
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18 characteristics were expected to be valued to a lesser extent. Thus, whilst the attributes health professionals expect their consumers to prefer are largely consistent with actual consumer and carer preferences, some inconsistencies in the relative priorities were seen. Notably, continued supply was the most important priority for consumers and carers, and pharmacy location was perceived to be highest priority by health professionals.
Discussion
This study provides evidence about the relative importance of different pharmacy service characteristics that are preferred by consumers and carers to assist with the management of their chronic condition(s). A substantial proportion of consumers and carers were willing to take up a new service, and one quarter always chose a new pharmacy service for every choice set, suggesting that the potential for innovative and well-designed pharmacy services to optimise consumer-centred care of chronic condition(s) has not yet been fully realised. New pharmacy services were more likely to be taken up by younger consumers and carers, those in employment or with a higher level of education, and those with established as opposed to newly diagnosed chronic condition(s). The reason these consumer and carer subgroups in particular are more likely to take up new services was not explored. However, it is possible that these groups are more likely to accept or adopt innovation. It is also possible that these groups are underserviced by current Australian pharmacy services. It would therefore be important to explore the reasons behind this finding in further studies.
Nevertheless, this finding is consistent with a previous study in Scotland that also found younger people were more likely to take up innovative new services. 15 Recognition that pharmacy services could alleviate unmet health needs of young New Zealanders 23 has been accompanied by calls that new services are youth-friendly and developed in consultation with young people. 51 Although this population does not currently constitute the bulk of those with chronic conditions in most countries, they do represent a group with preventative potential.
By adequately servicing this population and capitalising on their willingness to try innovative pharmacy initiatives, it may be possible to stem the wave of chronic disease costs in future.
Improvements in pharmacy service characteristics could produce worthwhile benefits, particularly for these subgroups.
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It is notable that continued supply of prescription medicines by a pharmacist after an existing prescription runs out, particularly involving a supply of medicines that had been used before to manage symptom flare ups, was a high priority characteristic for consumers and carers. Pharmacist prescribing has already been implemented to varying extents in a number of countries including the United Kingdom, United States, Canada and New Zealand.
12, 13, 52
However, in Australia, pharmacist prescribing initiatives remain very limited, occurring only within small pilot study schemes. 53 Recent initiatives in Australia have allowed "medication continuance" by pharmacists for lipid lowering agents and contraceptive medicines, without a written prescription, in specified circumstances. 54 However, this initiative is more akin to continued dispensing to ensure no break in supply, rather than formal repeat prescribing.
Previous research has shown consumer preferences to support pharmacist repeat prescribing in Scotland, 15 and pharmacist independent prescribing in England. 16 Our findings provide considerable consumer and carer support for the provision of continued supply of regular and flare up medicines that have been previously prescribed by a medical practitioner in Australia. Obviously, this practice would need to occur under agreed guidelines by appropriately trained pharmacists and with regular (i.e. annual) visits and review by the GP.
Expanding roles for health professionals including pharmacists are being driven in part by an imperative to find new models of care to sustain the over-burdened health system.
In many countries, population growth and ageing is leading or expected to lead to pressures on the health work force and its capacity to maintain service delivery. This pressure is promoting the development of new models of care, for example telehealth, or new strategies for more affordable skill mix. In some areas, including Australia in which large population segments reside in underserviced rural and remote regions, these pressures are heightened by access inequities. Over 4 million (3.3%) GP visits annually in Australia relate to a repeat prescription for a medicine that has been used before. 11 Some commentators have emphasised the potential for expansion of pharmacist roles, for example to include repeat prescribing, as a safe and cost-effective strategy to address workforce pressures. 11 In Australia, pharmacists are generally in support of an expanded prescribing role, 55, 56 although there has been little research into the opinions of other stakeholders, including the public. 57 This preference study provides evidence that a pharmacist supplementary prescribing initiative would likely be acceptable for the majority of consumers with chronic condition(s), and indeed may be a desirable service for many Australian consumers -particularly younger adults, those in employment, frequent medicine users, and those with an established diagnosis.
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Pharmacy location in a "one-stop health centre" was also highly valued. A health hub might be seen as attractive as it provides coordination of services as well as convenience.
Previous research has also confirmed the desirability of pharmacy as part of a one stop health hub as a proactive approach to care, encompassing advice and medication management, referral alongside assistance with health system navigation, and even health advocacy. 32 Although the preference for availability of home delivery of medicines was expected, the aversion to the availability of medicine pick up without going into a pharmacy, for example by "drive thru", was unexpected, as preliminary work indicated convenience to be a highly desirable characteristic. 32, 33 The option of "face-to-face pick up or drive thru" was valued less on average than face-to-face pick up alone. "Drive-thru" services are routinely provided in other markets in Australia (e.g. fast food, alcohol). However, qualitative comments made by consumers and carers in response to the survey suggested one reason for not choosing a new service pertained to the safety and lack of personal contact associated with drive through options. The findings suggest that although consumers and carers value convenience highly, they identify pharmacy and medicines use services, and perhaps health care services more generally, as inappropriate commodities for impersonal services.
Despite the majority choosing to take up a new service on one or more occasions, a considerable proportion of our sample declined to choose a new service. This preference was predominantly explained by three reasons; the existence of high quality person-centred services based on positive long-term relationships and continuity, the convenience of existing services (in terms of speed and location), and the responsiveness of current services to their medication needs, including the reliable provision of medication supply and timely expert advice. These reasons mirrored those that were identified as important service characteristics in earlier qualitative stages of the larger project within which this study sits. 32, 33 It would seem that if participants are receiving these three qualities from their current pharmacy, the need for innovative services is negated. When compared against these fundamental qualities, new services were rarely viewed as an advantage. A strong tendency to favour the status quo in healthcare choices has been previously acknowledged, 58 and our findings are consistent with previous studies indicating a large group of loyal consumers. 15, 59 However, previous studies have seldom explored the reason for this loyalty. Our findings show that high quality, convenient, person-centred pharmacy services that are responsive to consumer and carer medicine needs are fundamental requirements for most consumers.
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The overall consensus between health professional perceptions of consumer needs and actual consumer and carer preferences suggests health professionals are largely empathetic to what their consumers and carers require in a pharmacy service. By implication, this would suggest health professionals have an understanding of consumer and carer preferences, and service provision is likely to be largely consistent with consumer and carer desires. It is interesting, but perhaps not surprising, that newly qualified health professionals, and those who were consumers with chronic condition(s) or carers themselves, were more sympathetic to the value consumers placed on continued medicines supply. The key difference between health professionals, and consumers and carers was the reverse order of priorities, with continued supply being most important for consumers and carers, and convenience of location perceived to be most important by health professionals. Both these characteristics relate to aspects of easy access. However, consumers and carers valued the convenience and/or cost avoidance afforded by eliminating the need for some doctor visits more strongly than was perceived to be the case by health professionals. 42 51.8% were female (current survey 70.1%) and 16.6% were 65 years or over (current survey 33.6% were 66 years or over). Of subgroups with selected chronic conditions in the NHS, 89.5% spoke English as their main language at home (96.2% in current survey), and 65.4% were employed in the labour force (27.1% in current survey). Therefore females, older adults and those speaking English at home were over-represented and the employed were under-represented in the current survey as compared to the Australian NHS population with chronic condition(s). However, any comparison of the DCE survey sample with the NHS needs to consider the differing aims and selection processes for the studies. The differences in participant characteristics between the current M A N U S C R I P T
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survey and the NHS likely reflects the focussed aim of the current preference study to access the opinions of individuals who were extensive users of pharmacy and healthcare services, as well as those who were not; whereas, the NHS was a population survey designed to obtain national benchmark information on a range of health related issues (including risk factors and disability) and to enable the monitoring of trends in health over time.
Regardless, the limited number of participant characteristics that were associated with preference for service characteristics in the current study suggests that preferences for pharmacy service characteristics are unlikely to change substantially between different subgroups of people with chronic condition(s), suggesting that our findings may be generalisable to the Australian population with chronic condition(s) and their carers.
Nevertheless, this study should be repeated in other samples to confirm the findings and examine the stability of choices in different sub-samples. Some counter intuitive findings emerged from our study, warranting further investigation. Specifically, consumers and carers in employment were more averse to service cost than those not in employment. Although employment was moderately correlated with income, income was not significantly associated with preference heterogeneity around service cost. Thus, it seems possible that those in employment may have a greater financial burden associated with their medicines use (as they have limited access to concession schemes), than those not in employment and may arguably be more cost averse. This assertion requires empirical confirmation.
A limitation of this study was the use of more than one data collection mode. This situation is not ideal in that it assumes no systematic effect of the mode on the responses, which may not be the case. However, this approach was used to ensure the size and diversity of the sample (i.e. access to those who were not easily reached by telephone) and convenience for participants. Another limitation was the use of hypothetical discrete choice questions in the survey based on the assumption that participants would choose in reality the services they indicated. Although DCEs in general make this assumption, the indirect elicitation nature of the DCE task has been argued to overcome any hypothetical bias, as compared to alternative preference elicitation methods. 60 Moreover, the DCE enables elicitation of preferences for services including new services for which revealed market preference data are not available, as is the case here. MXL requires a distributional assumption to be made for the data, and this could be considered a disadvantage of the MXL analytic approach. Nevertheless, the assumption of a normal distribution for all random M A N U S C R I P T
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parameters in the MXL analyses is commonly applied in health-related DCEs. 29 Finally, our comparison of the preferences of consumers and carers with the perceptions of health professionals may be limited by the DCE design, in that consumers and carers were offered an opt out alternative of their current pharmacy service, whereas health professionals were not. However, this difference was necessary for realism. An opt out was necessary for consumers and carers who would not have to take up a new service in reality; whereas, such a choice for health professionals who were asked to provide their perception of consumers preferred choice would not be sensible (since they have no knowledge of the consumers current service).
CONCLUSION
This study emphasises the fundamental importance, from the consumer and carer perspective, of the provision of high quality and convenient person-centred pharmacy services that are responsive to their needs. Pharmacy can deliver substantially greater benefits for consumers with chronic condition(s) and carers through well-designed services that attend to these fundamental characteristics. This is particularly the case for younger consumers and carers, those in employment, more highly educated, and those with established as opposed to newly diagnosed condition(s). Targeting these groups with new and innovative pharmacy services that align to their unique needs presents an opportunity for improving the management of chronic condition(s) in the community, reducing overall treatment burden.
The provision of continued medicines supply (e.g. through pharmacist prescribing), convenient and coordinated care in a one stop health centre, and home delivery in particular, should be prioritised when planning pharmacy services to assist consumers to manage chronic conditions. Bars are colour coded for attributes; order of legend is consistent with order of bars.
Size of bar represents relative value of a gain in attribute from the least preferred level (defined in Figure 4 ). ***, ** ==> Relevant parameter (numerator for the rescaled weights) was significant in model at 1%, 5% level. Bars are colour coded for attributes; order of legend is consistent with order of bars.
Size of bar represents relative value of a gain in attribute from the least preferred level (defined in Figure 4 ). ***, ** ==> Relevant parameter (numerator for the rescaled weights) was significant in model at 1%, 5% level. 
Medicines review or advice
The pharmacist is in the dispensary and you can ask to speak to them The pharmacist is available in the pharmacy without you needing to ask The pharmacist is available in the pharmacy without you needing to ask and you can speak to the pharmacist by phone, email, or internet The pharmacist is available in the pharmacy without you needing to ask and you can make an appointment for the pharmacist to visit you at home Affordability (i.e. Pharmacy staff available to speak with you and direct you to other health services, which you can then access yourself (e.g. dieticians)
M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT
You can get advice from other health providers who are employed in the pharmacy (e.g. dieticians)
Pharmacy location Pharmacy that is located near to your GP practice only
Pharmacy that is located near to your home or work but away from other health services
Getting your medicines Face to face pick up at pharmacy
Face to face pick up at pharmacy and you can collect your medicines without going into the pharmacy if required (e.g. drive thru)
Medicines review or advice
The pharmacist is available in the pharmacy without you needing to ask and you can make an appointment for the pharmacist to visit you at home 
